Mutated BRAF is detected in approximately 45% of papillary thyroid carcinomas (PTC). To
model PTC, we bred mice with adult-onset, thyrocyte-specific expression of BRAFV600E …

The BRAFT1799A mutation is the most common genetic alteration in papillary thyroid
carcinomas (PTC). It is also found in a subset of papillary microcarcinomas, consistent with a …

Abstract Context: Although the BRAF V600E mutant can initiate the formation of papillary
thyroid cancer (PTC), it is unclear whether it is required to maintain cell proliferation …

The activating mutation BRAF T1796A is the most prevalent genetic alteration in papillary
thyroid carcinomas (PTC). It is associated with advanced PTCs, suggesting that this …

The mutant BRAF (BRAFV600E) is the most common genetic alteration in papillary thyroid
carcinomas (PTCs). The oncogenicity of this mutation has been shown by some genetically …

Mutations of BRAF are found in∼ 45% of papillary thyroid cancers and are enriched in
tumors with more aggressive properties. We developed mice with a thyroid-specific knock-in …

Papillary thyroid cancer (PTC) is the most common endocrine malignancy, accounting for 85–
90% of all thyroid cancers. Genetic alternations involving the mitogen-activated protein …

Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Purpose: Oncogenic conversion of BRAF occurs in∼ 44% of papillary thyroid carcinomas
and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is …